10 Best Hot Stocks To Buy Right Now

4. Geron Corporation (NASDAQ:GERN)

Number of Hedge Fund Holders: 26

Year-to-Date Share Price Gains: 106.07%

Average Price Target Upside: 58.73%

Geron Corporation (NASDAQ:GERN) is a biopharmaceutical company focused on transforming the treatment of blood cancers. Its flagship product, RYTELO (imetelstat), has been approved in the United States for specific adult patients suffering from lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia.

The company is running an important Phase 3 clinical trial for imetelstat in patients with myelofibrosis who have either relapsed or did not respond to JAK inhibitors. It is also exploring the drug’s potential to treat other types of blood cancers. Imetelstat works by blocking telomerase activity, which is usually higher in harmful stem and progenitor cells. The action aims to slow down their growth and help kill these cancerous cells.

Doctors and patients are excited about Rytelo’s ability to help those with lower-risk MDS, especially patients who need blood transfusions. It can be accessed within 24-48 hours in most states

In addition, Geron (NASDAQ:GERN) has requested a patent extension until August 2037 and is working on expanding its availability, including submitting a marketing application in the EU.

On September 9, The Fly reported that Analyst Faisal Khurshid from Leerink started coverage on the company stock with an Outperform rating and a $7 price target. According to the analyst, it is a Top Pick in the Emerging Immunology sector.

Leerink is optimistic about Geron’s (NASDAQ:GERN) future, especially for the year 2025, as it believes Rytelo could become a top-selling treatment for LR-MDS. The firm expects to see this reflected in the company’s quarterly revenue starting in 2025.